<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132324</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 59872-102</org_study_id>
    <nct_id>NCT03132324</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease</brief_title>
  <official_title>A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability, and the pharmacokinetic
      and biologic activity of INCB059872 in participants with sickle cell disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of INCB059872 assessed by monitoring frequency, duration, and severity of adverse events</measure>
    <time_frame>Screening through 35 days after end of treatment, up to approximately 3 months per participant.</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fetal hemoglobin (HbF) from baseline</measure>
    <time_frame>Baseline through 2 weeks after end of treatment, up to approximately 2.5 months per participant.</time_frame>
    <description>Pharmacodynamic activity assessed by measuring changes of HbF from baseline and their correlation to INCB059872 treatment. The HbF (F cells) in human whole blood will be characterized using flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of INCB059872</measure>
    <time_frame>Baseline to Day 28.</time_frame>
    <description>Defined as maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of INCB059872</measure>
    <time_frame>Baseline to Day 28.</time_frame>
    <description>Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>INCB059872 QOD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial cohort dose of INCB059872 at the protocol-specified starting dose once every other day (QOD), with subsequent cohort escalations based on protocol-specific criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB059872 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the first 3 dose cohorts have been evaluated for tolerability of a QOD schedule, a parallel cohort will evaluate a once-daily (QD) schedule with subsequent dose escalations based on protocol-specific criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB059872</intervention_name>
    <description>INCB059872 at the protocol-defined dose administered QOD or QD based on cohort assignment.</description>
    <arm_group_label>INCB059872 QOD</arm_group_label>
    <arm_group_label>INCB059872 QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of SCD (sickle cell SS) confirmed through hemoglobin electrophoresis.

          -  Must be red blood cell (RBC) transfusion-independent (not currently on regularly
             scheduled transfusions) for ≥ 3 months from the time of first dose of study drug.

          -  No RBC transfusion within 30 days of first dose of study drug.

          -  Hydroxyurea (HU) refractory

             -Must not have received HU therapy during the 3 months before receiving study drug.

          -  Creatinine clearance ≥ 60 mL/min based on the institutional formula.

          -  Willingness to avoid pregnancy or fathering children.

        Exclusion Criteria:

          -  Any unresolved toxicity ≥ Grade 2 from previous therapy except for stable chronic
             toxicities not expected to resolve.

          -  Pregnant or nursing women or participants expecting to conceive or father children
             within the projected duration of the study, starting with screening visit through
             completion of safety follow-up.

          -  Received an investigational study drug within 28 days or 5 half-lives (whichever is
             longer) before receiving the first dose of study drug (requirement may be waived with
             medical monitor approval).

          -  Chronic or current active infectious disease requiring systemic antibiotics,
             antifungal, or antiviral treatment.

          -  Prior receipt of LSD1 inhibitor therapy for any indication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fitzroy Dawkins, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Acevedo Clinical Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle cell disease (SCD)</keyword>
  <keyword>sickle cell SS</keyword>
  <keyword>lysine demethylase 1 (LSD1) inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

